Current filters:


1 to 9 of 293 results

EC backs continued use of pioglitazone drugs for diabetes


Japan’s largest drugmaker, Takeda Pharmaceutical (TYO 4502) said yesterday that the European Commission…

ActosDiabetesEuropePharmaceuticalPioglitazoneRegulationTakeda Pharmaceuticals

Merck & Co drops combo diabetes drug Janacti filing in Europe; presents data on discontinued vorapaxar study


The European Medicines Agency says it has been formally notified by Merck Sharp & Dohme (Europe), a subsidiary…

Cardio-vascularDiabetesJanactiMerck & CoPharmaceuticalPioglitazoneRegulationResearchsitagliptinvorapaxar

US FDA sets PUDFA date for Takeda diabetes drug alogliptin and fixed-dose alogliptin/pioglitazone


The US subsidiary of Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) said yesterday…

alogliptinDiabetesNorth AmericaPharmaceuticalPioglitazoneRegulationTakeda Pharmaceuticals

Prior CHMP positive benefit-risk for pioglitazone confirmed; EMA starts NSAIDS review


The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has clarified its…

ActosDiabetesEuropeNeurologicalPharmaceuticalPioglitazoneRegulationTakeda Pharmaceuticals

Takeda’s 3rd quarter profits hit by in-licensing costs and sales declines for Actos and Prevacid


Japan’s largest drugmaker Takeda posted results for the nine months ended December 31, 2009, reporting…

ActosFinancialLansoprazolePharmaceuticalPioglitazonePrevacidPrevacid NapraPAC

1 to 9 of 293 results

Back to top